Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material

Autor: Elisabeth M. P. Steeghs, Leonie I. Kroeze, Bastiaan B. J. Tops, Leon C. van Kempen, Arja ter Elst, Annemiek W. M. Kastner-van Raaij, Sandra J. B. Hendriks-Cornelissen, Mandy J. W. Hermsen, Erik A. M. Jansen, Petra M. Nederlof, Ed Schuuring, Marjolijn J. L. Ligtenberg, Astrid Eijkelenboom

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)

Abstract Background Sensitive and reliable molecular diagnostics is needed to guide therapeutic decisions for cancer patients. Although less material becomes available for testing, genetic markers are rapidly expanding. Simultaneous detection of pred

Externí odkaz: https://doaj.org/article/80b46644a0ac4a81a543ea91a367776e

Micro-costing diagnostics in oncology

Autor: Edwin Cuppen, Katrien Grünberg, Valesca P. Retèl, Clémence T. B. Pasmans, Veerle M.H. Coupé, Geert W.J. Frederix, Stefan M. Willems, Eiko K. de Jong, Elisabeth M. P. Steeghs, Bastiaan B. J. Tops, Ed Schuuring, Ewart de Bruijn, Marjolijn J. L. Ligtenberg, Hans van Snellenberg

Publikováno v: Expert Review of Pharmacoeconomics and Outcomes Research, 21, 3, pp. 413-414
Expert Review of Pharmacoeconomics and Outcomes Research, 21(3), 413-414. Taylor and Francis Ltd.
Pasmans, C T B, Tops, B B J, Steeghs, E M P, Coupé, V M H, Grünberg, K, de Jong, E K, Schuuring, E M D, Willems, S M, Ligtenberg, M J L, Retèl, V P, van Snellenberg, H, de Bruijn, E, Cuppen, E & Frederix, G W J 2021, ' Micro-costing diagnostics in oncology : from single-gene testing to whole-genome sequencing ', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 21, no. 3, pp. 413-414 . https://doi.org/10.1080/14737167.2021.1917385
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 413-414
Expert Review of Pharmacoeconomics and Outcomes Research, 21(3), 413-414. Taylor & Francis
Expert review of pharmacoeconomics & outcomes research, 21(3), 403-414. Taylor & Francis Group

PurposePredictive diagnostics play an increasingly important role in personalized medicine for cancer treatment. Whole genome sequencing (WGS) based treatment selection is expected to rapidly increase worldwide. Detailed and comparative cost analyses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f66fd597bbfc2a0732307af18e3d213
https://doi.org/10.1080/14737167.2021.1917385

Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.

Autor: Subhashis Sarkar, Wilfred T V Germeraad, Kasper M A Rouschop, Elisabeth M P Steeghs, Michel van Gelder, Gerard M J Bos, Lotte Wieten

Publikováno v: PLoS ONE, Vol 8, Iss 5, p e64835 (2013)

BACKGROUND: Multiple Myeloma (MM) is an incurable plasma cell malignancy residing within the bone marrow (BM). We aim to develop allogeneic Natural Killer (NK) cell immunotherapy for MM. As the BM contains hypoxic regions and the tumor environment ca

Externí odkaz: https://doaj.org/article/23c9693466bd40a2bb31b7457ccd8acc

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia

Autor: Isabel S. Jerchel, Marco J. Koudijs, Martin A. Horstmann, Aurélie Boeree, Monique L. den Boer, Rob Pieters, Alex Q. Hoogkamer, Willemieke de Goffau-Nobel, Elisabeth M. P. Steeghs, Cesca van de Ven, Nicolle Besselink, Judith M. Boer, Christian M. Zwaan, Hester A. de Groot-Kruseman

Publikováno v: Oncotarget, 8(52), 89923. Impact Journals
Oncotarget, 8(52), 89923-89938. Impact Journals LLC
Oncotarget

Background In high risk pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients, gain of function mutations and translocations affecting JAK2 have been described. These mutations and translocations result in aberrant kinase signali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782dd664b67e8abfb306426d86444364
https://hdl.handle.net/1765/102601

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia

Autor: Monique L. den Boer, Femke Stalpers, Valerie de Haas, Quirine J. Hartman, Marjolein Bakker, Elisabeth M. P. Steeghs, Judith M. Boer, Rob Pieters, Alex Q. Hoogkamer, Gabriele Escherich, Hester A. de Groot-Kruseman

Publikováno v: Scientific Reports, 8:693. Nature Publishing Group
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports

Approximately 25% of the pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases are genetically unclassified. More thorough elucidation of the pathobiology of these genetically unclassified (‘B-other’) cases may identify novel tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9da72c0538e6fdccde2490a9f7839b2
https://pure.eur.nl/en/publications/399ab89e-4a56-4465-9440-e965ede18bd4